17 February 2026

Oncoinvent to Present Positive 24-month Follow-up Data from Phase 1 Ovarian Cancer Study of Radspherin[®] at ESGO 2026

Oslo, Norway, 17 February 2026 – Oncoinvent (OSE: ONCIN), a biotech developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announced that it will present final 24‑month results from its RAD-18-001 Phase 1 study of Radspherin® after cytoreductive surgery in patients with platinum‑sensitive epithelial ovarian cancer and peritoneal recurrence at the European Society of Gynaecological Oncology (ESGO) 2026 Congress, taking place in Copenhagen, Denmark, from 26-28 February 2026.

Radspherin® is an intraperitoneal alpha-emitting therapy (224Ra-labeled microparticles), targeting remaining cancer cells while sparing healthy tissue within the peritoneal cavity to address microscopic residual disease following cytoreductive surgery, to prevent recurrence and enhance long-term patient outcomes.

The poster presentation, titled ‘Safety and efficacy results from a phase 1 study of intraperitoneal alpha-emitting radium-224 labelled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer,’ will share final 24-month data from the Phase 1 study detailing:

  • 21 patients enrolled across dose levels with a favourable safety profile and no dose‑limiting toxicities observed
  • No grade ≥3 adverse events considered related to Radspherin®
  • Recommended dose selected at 7 MBq following dose escalation
  • Durable local disease control signal at 24 months: only 1 of 10 patients treated at the recommended dose  experienced peritoneal recurrence

“We are pleased to present our Phase 1 data at the ESGO 27th Annual Meeting, an important forum for sharing findings with the international gynecologic oncology community. These encouraging data reflect the collaborative efforts of the study team and the potential of Radspherin® to address a patient population with high risk of peritoneal recurrence and poor prognosis,” said Yun Wang, MD, PhD, Department for Cancer Surgery, Section for Gynecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, principal investigator in the RAD-18-001 trial.

Chief Medical Offer Kari Myren at Oncoinvent added, “We remain committed to advancing Radspherin® in the Phase 2 trial and to further evaluating its potential to benefit patients with ovarian cancer.”

Details of the presentation are as follows:

Poster title: Safety and efficacy results from a phase 1 study of intraperitoneal alpha-emitting radium-224 labelled microparticles after cytoreductive surgery in patients with peritoneal recurrence of platinum-sensitive epithelial ovarian cancer
Presenter: Yun Wang, Department of Surgical Oncology Section of Gynaecological Cancer, Norwegian Radium Hospital, Oslo University Hospital
Authors: Y. Wang1, E. Van Nieuwenhuysen2, L. Chiva3, E. Chacon4, M-E. Revheim1,5, CM. Deroose2, L. Sancho3, JJ. Rosales Castillo4, A-K. Aksnes6, K. Myren6, I. Vergote2, ØS. Bruland1,5
Session title: Poster walk
Session date and time: 27 February 2026, 17:20-18:20 CET
Location: Exhibition
Abstract ID: 938

Abstracts are available on the ESGO program guide here, and the poster once presented will be available at Oncoinvent’s website here.

1 The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
2 University Hospital Leuven and KU Leuven, Leuven, Belgium
3 Clínica Universidad de Navarra, Madrid, Spain
4 Clínica Universidad de Navarra, Pamplona, Spain
5 University of Oslo, Oslo, Norway
6 Oncoinvent Solutions AS, Oslo, Norway

***

For further information, please contact:
Øystein Soug, CEO
Email: IR@oncoinvent.com

Optimum Strategic Communications
Zoe Bolt, Elena Bates, Katherine Bliss
+44 (0) 203 882 9621
oncoinvent@optimumcomms.com 



About Oncoinvent

Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.

This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.

Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).

Øystein Soug

Chief Executive Officer

soug@oncoinvent.com

Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.

Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997

close

Anders Månsson

Chief Executive Officer

mansson@oncoinvent.com

Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.

Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.

close